DoW Peer Reviewed Medical, Research Advancement Award

The DoW Peer Reviewed Medical, Research Advancement Award supports fundamental research studies that will make an important contribution towards research, patient care, and/or quality of life for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP portfolio-specific strategic goals. The award supports use-inspired basic research to further or validate preliminary findings for short- and long-term impact. Proposed research projects may range from hypothesis testing to expansion of mature data. • The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $19.6M to fund approximately 14 Research Advancement Award applications with total cost caps of $1.4M per award. • The maximum period of performance is 4 years. • Awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032.